BioCentury
ARTICLE | Clinical News

Bayer's riociguat meets Phase III PAH endpoint

October 23, 2012 1:07 AM UTC

Bayer AG (Xetra:BAYN) said riociguat with or without endothelin receptor antagonists/non-IV prostanoids met the primary endpoint of improving six-minute walk test (6MWT) distance from baseline to week...